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1. Introduction
1.1. Identification and annotation of the DSCR
Down syndrome (DS) is a very complex disorder that requires, even more than other human
genetics diseases, a “system level” understanding [1,2], both under the clinical and under the
molecular genetics perspectives. Under the clinical point of view, all individuals affected by
Down syndrome are characterized by learning disabilities, distinctive facial features, and low
muscle tone (hypotonia) in early infancy. However, in most cases the clinical picture is
complicated by additional problems, such as heart defects, leukemia, and early-onset Alz‐
heimer's disease [3,4]. The degree to which an individual is affected by these characteristics
varies from mild to severe. After the pioneering description by J.L. Down in 1866, almost one
century was needed to decipher the etiology of the syndrome. The work of Lejeune proved
that DS was caused by an extra copy of chromosome 21 (HSA21) [5], thus providing the first
evidence for a genetic basis of intellectual disability. The main implication of this seminal
discovery is that the complex phenotype seen in DS patients [6] must be caused by overdosage
of HSA21 genes. However, it also raised the outstanding questions of whether one or few
HSA21 genes may play a dominant role in the syndrome and whether specific HSA21 genes
could contribute to specific phenotypic tracts. Answering these questions is still of paramount
importance, because the identification of one or few ‘dominant’ molecular players could pave
the road for the development of targeted therapeutic approaches. The development of
molecular karyotyping has provided strong support to the view that a restricted region of
HSA21, commonly referred to as Down Syndrome Crtitical Region (DSCR) might be respon‐
sible for the different phenotypes that characterize DS. In 1976 Poissonnier and coworkers, by
using chromosome staining methods, found that one DS patient not possessing an extra HSA21
had only a partial trisomy, involving 21q22.1 and 21q22.2 bands [7]. Afterwards, it turned out
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that partial trisomies are responsible for approximately 1% of DS cases [8,9]. These patients
show variable phenotypes, depending on the extension of the triplicated region. Therefore,
partial trisomies of genes carried by chromosome 21 have been extremely valuable in inves‐
tigating the involvement in DS. The analysis of 10 partial trisomy patients, [10] suggested that
two regions of chromosome 21 were linked to most of the Jackson signs [3], including cognitive
disorders. These regions, referred to has DCR-1 and DCR-2, respectively, encompassed the
21q22.2 band and were located around the D21S55 Site Targeted Sequence (STS) and between
D21S55 and the MX1 gene, respectively. Korenberg and coworkers studied a different
population and observed that the proximal and distal regions of the 21q arm were also
associated with the full DS phenotype [11]. Although these studies confirmed the strong
association of DS phenotypes with the DCR-1 region, they also suggested that DS is a contig‐
uous gene syndrome, arguing against a single DS chromosomal region responsible for most
of the DS phenotypic features [11]. More recently, an additional causal link of the region located
between D21S17 and ETS2 to clinical features of DS was confirmed through lattice analysis
[12]. Although the notion of a DSCR has gained wide acceptance in DS research, it must be
underscored that some of the data that support it remain controversial and that its existence
has recently come under considerable question. Indeed, a detailed study of segmental trisomy
21 in DS subjects, performed by using array comparative genome hybridization (GCH),
excludes the implication of a single but rather suggest that multiple regions of HSA21
contribute to many of the phenotypes of DS, including intellectual disability DSCR [13].
Despite these apparent inconsistencies, we think that, in practical terms, the crucial point is
not to prove whether one or more “critical region” exist, but rather to understand which
dosage-sensitive genes contribute to specific DS phenotypes. Indeed, it is quite clear that the
classical “reductionist” approach of identifying one or few master genes, which has been very
successful in the case of Mendelian disorders, is not appropriate to unravel the extremely more
complicated case of DS. In this case, the overall phenotype is certainly produced by the
combined action of several genes, causing complex rearrangements of different molecular
networks [14]. The relevance of the mentioned studies has been to restrict the list of HSA21
genes that may contribute more significantly to the clinical manifestations.
For these motivations, in Tables 1 and 2 we adopt an inclusive definition of the DSCR, which
extends from the RCAN1 gene to the MX1 gene. This definition takes into account not only
the putative borders that have been identified in the mentioned studies, but also the fact that
the RCAN1 gene as been commonly considered as part of the DSCR, even though a precise
mapping on the current release of the human genome sequence (HG19) would locate it outside
the centromeric border defined by [12]. Obviously, the usefulness of this information will
strongly depend on the degree of functional characterization of the genes comprised in the
interval. Under this respect, as it is generally true for the human genome, it must be recognized
that our knowledge is still quite limited.
HSA21 was one of the first human chromosomes to be fully sequenced [15]. Nevertheless, the
list of the possible functional sequences located in the DSCR has progressively changed, not
only for the uncertainty of defining precise borders, but especially for the changes in the current
view of what a human gene is. Obviously, the initial emphasis has been to identify the protein-
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coding sequences, whose number is approximately of 40, on the basis of a comprehensive
definition of the DSCR and of the present annotation of the human genome (Table 1). However,
systematic studies performed in the last few years revealed that many genomic sequences that
have been initially considered as “junk DNA”, are endowed with extremely relevant functional
potential [16]. Indeed, genome-wide interrogations have revealed that a large majority of the
human genome is transcribed and that a significant proportion of transcripts appears to be
non-protein coding (ncRNA). Although it is well recognized that some ncRNAs play essential
enzymatic activities in translation, splicing and ribosome biogenesis, the functions of most
ncRNAs are still unknown. It is now believed that they could participate in complex regulatory
circuits responsible for the fine-tuning of gene expression at both the transcriptional and post-
transcriptional levels [16]. The best known ncRNAs are miRNAs, ~22 nucleotide-long mole‐
cules that mediate post-transcriptional gene silencing by binding complementary sequences
located in the 3’ UTR of the mRNAs. Long intergenic ncRNAs (lincRNA) represent a less
characterized but more abundant and heterogeneous class, and comprise transcripts longer
than 200 nt involved in many biological processes, including transcriptional control, epigenetic
modification and post-transcriptional control on mRNAs [16]. A recent discovery demonstrat‐
ed that both mRNAs and ncRNAs can deploy their functions by contributing to an extensive
RNA-RNA interaction network, based on the competition of these molecules for the binding
of shared miRNAs (the ceRNA hypothesis) [17-20]. Importantly, transcribed pseudogenes
could also be involved in these complex regulatory interactions [21]. In light of this growing
complexity, we think that the presence of many ‘non conventional’ sequences within the DSCR
should be taken into consideration when exploring the molecular consequences of an increased
dosage of this region. We provide an updated list of them in Table 2.
DCR Gene Name EntrezGene ID Main molecular function Essential references
Expression in
adult brain
1 RCAN1 1827 CaN inhibitor See main text Yes
1 CLIC6 54102 Channel See main text Yes
1 RUNX1 861 Transcription factor See main text Yes
1 SETD4 54093 Unknown No information Yes
1 CBR1 873 Enzyme [165] Yes
1 CBR3 874 Enzyme [165]
1 DOPEY2 9980 Unknown [166] Yes
1 MORC3 23515 RNA-binding [167]
1 CHAF1B 8208 Chromatin assembly [168] Yes
1 CLDN14 23562 Tight junctions component [169]
1 SIM2 6493 Transcription factor See main text Yes
1 HLCS 3141 Enzyme [170] Yes
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DCR Gene Name EntrezGene ID Main molecular function Essential references
Expression in
adult brain
1 DSCR6 53820 Unknown [171] Yes
1 PIGP 51227 Enzyme [172] Yes
1 TTC3 7267 E3 ligase See main text Yes
1 DSCR3 10311 Unknown [173] Yes
1 DYRK1A 1859 Protein kinase See main text Yes
1-2 KCNJ6 3763 Channel See main text
1-2 DSCR4 10281 Unknown [174]
1-2 DSCR8 84677 Unknown [175]
1-2 KCNJ15 3772 Channel [176]
1-2 ERG 2078 Transcription factor See main text Yes
1-2 ETS2 2114 Transcription factor See main text Yes
2 PSMG1 8624 Chaperone [177] Yes
2 BRWD1 54014 Transcription factor See main text Yes
2 HMGN1 3150 Transcription factor See main text Yes
2 WRB 7485 Protein trafficking [178] Yes
2 LCA5L 150082 Ciliary protein [179]
2 SH3BGR 6450 Unknown No information Yes
2 B3GALT5 10317 Enzyme [180]
2 C21orf88 114041 Unknown No information Yes
2 IGSF5 150084 Adhesion molecule [181]
2 PCP4 5121 Unknown [182] Yes
2 DSCAM 1826 Adhesion molecule [183]
2 BACE2 25825 Protease See main text Yes
2 FAM3B 54097 Cytokine [184]
2 MX2 4600 Unknown [185]
2 MX1 4599 Unknown [185] Yes
Table 1. Summary of the protein-coding genes contained by the DSCR. The first column indicates whether the genes
belong to the DCR-1, to the DCR-2 or to the overlap region. The evidence for expression in adult brain is derived from
the EVOC data [186] contained in the Ensembl genome browser. Genes are given in their physical order, starting from
the more centromeric sequence.
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DCR Gene Name Ensembl ID
Entrez
Gene ID
HSA21 coordinates Gene Biotype
Evidence of
expression
(EST)
1 LINC00160 ENSG00000230978 54064 36096105 - 36109478 lincRNA
1 AP000330.8 ENSG00000234380 100506385 36118054 - 36157183 Antisense
1 AF015262.2 ENSG00000234703 36508935 - 36511519 lincRNA +
1 RPL34P3 ENSG00000223671 54026 36844395 - 36844730 Pseudogene +
1 EZH2P1 ENSG00000231300 266693 36972030 - 36972320 Pseudogene
1 AF015720.3 ENSG00000230794 37085437 - 37105240 processed transcript +
1 MIR802 ENSG00000211590 768219 37093013 - 37093106 miRNA
1 RPS20P1 ENSG00000229761 54025 37097045 - 37097398 Pseudogene
1 PPP1R2P2 ENSG00000234008 54036 37259493 - 37260105 Pseudogene
1 AP000688.8 ENSG00000231106 37377636 - 37379899 lincRNA +
1 RPL23AP3 ENSG00000214914 8489 37388377 - 37388844 Pseudogene ++
1 RIMKLBP1 ENSG00000189089 54031 37422512 - 37423675 Pseudogene
1 AP000688.11 ENSG00000236677 37432730 - 37436706 Antisense +
1 U6 ENSG00000200213 1497008 37438843 - 37438950 snRNA
1 AP000688.14 ENSG00000230212 100133286 37441940 - 37498938 sense intronic
1 AP000688.15 ENSG00000236119 37455157 - 37462712 lincRNA +
1 AP000688.29 ENSG00000233393 37477179 - 37481988 lincRNA +
1 MEMO1P1 ENSG00000226054 728556 37502669 - 37504208 Pseudogene
1 CBR3-AS1 ENSG00000236830 100506428 37504065 - 37528605 lincRNA
1 RPS9P1 ENSG00000214889 8410 37504748 - 37505330 Pseudogene
1 RPL3P1 ENSG00000228149 8488 37541268 - 37542478 Pseudogene
1 Metazoa_SRP ENSG00000265882 37585858 - 37586136 miscellaneous RNA
1 snoU13 ENSG00000238851 37630724 - 37630829 snoRNA
1 SRSF9P1 ENSG00000214867 54021 37667471 - 37668000 Pseudogene
1 AP000692.9 ENSG00000228107 37732928 - 37734338 processed transcript +
1 ATP5J2LP ENSG00000224421 54100 37761176 - 37761410 Pseudogene
1 AP000695.6 ENSG00000230479 37802658 - 37853368 Antisense +
1 AP000695.4 ENSG00000233818 37818029 - 37904706 Antisense
1 PSMD4P1 ENSG00000223741 54035 37858281 - 37859709 Pseudogene +
1 AP000696.2 ENSG00000231324 38004979 - 38009331 lincRNA ++
1 AP000697.6 ENSG00000224269 38071073 - 38073864 Antisense +
1 HLCS-IT1 ENSG00000237646 100874294 38176285 - 38178585 sense intronic ++
1 RN5S491 ENSG00000199806 100873733 38224211 - 38224328 rRNA
1 AP000704.5 ENSG00000224790 38338812 - 38344128 lincRNA ++
1 Y_RNA ENSG00000207416 38359039 - 38359151 miscellaneous RNA
1 MRPL20P1 ENSG00000215734 359737 38366943 - 38367375 Pseudogene
1 U6 ENSG00000212136 1497008 38417830 - 38417936 snRNA
1 TTC3-AS1 ENSG00000228677 100874006 38559967 - 38566227 Antisense ++
1 DSCR9 ENSG00000230366 257203 38580804 - 38594037 lincRNA
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DCR Gene Name Ensembl ID
Entrez
Gene ID
HSA21 coordinates Gene Biotype
Evidence of
expression
(EST)
1 Metazoa_SRP ENSG00000263969 38587906 - 38588202 miscellaneous RNA
1 AP001432.14 ENSG00000242553 38593720 - 38610045 lincRNA +
1-2 KCNJ6-IT1 ENSG00000233213 100874329 39089405 - 39091872 sense intronic +
1-2 AP001427.1 ENSG00000264691 39334968 - 39335068 miRNA +
1-2 DSCR4-IT1 ENSG00000223608 100874327 39378846 - 39382920 sense intronic +
1-2 snoU13 ENSG00000238581 39559551 - 39559656 snoRNA
1-2 DSCR10 ENSG00000233316 259234 39578250 - 39580738 lincRNA
1-2 AP001434.2 ENSG00000226012 39609139 - 39610123 lincRNA +
1-2 SPATA20P1 ENSG00000231123 100874060 39610149 - 39610586 Pseudogene
1-2 AP001422.3 ENSG00000231231 39695557 - 39705343 lincRNA ++
1-2 SNRPGP13 ENSG00000231480 100874428 39874369 - 39874545 Pseudogene
1-2 LINC00114 ENSG00000223806 400866 40110825 - 40140898 lincRNA
2 AP001042.1 ENSG00000229986 40218171 - 40220568 lincRNA
2 AF064858.6 ENSG00000205622 400867 40249215 - 40328392 lincRNA
2 AP001043.1 ENSG00000229925 40260696 - 40275829 processed transcript +
2 SNORA62 ENSG00000252384 40266709 - 40266791 snoRNA
2 RPSAP64 ENSG00000227721 40266841 - 40267176 Pseudogene
2 AP001044.2 ENSG00000234035 40285093 - 40287072 lincRNA +
2 AF064858.7 ENSG00000232837 40346355 - 40349700 lincRNA +
2 AF064858.8 ENSG00000235888 40360633 - 40378079 lincRNA +
2 AF064858.11 ENSG00000237721 40378574 - 40383255 lincRNA +
2 AF064858.10 ENSG00000237609 40400461 - 40401053 lincRNA +
2 RPL23AP12 ENSG00000228861 391282 40499494 - 40499966 Pseudogene +
2 PCBP2P1 ENSG00000235701 54040 40543056 - 40544032 Pseudogene
2 TIMM9P2 ENSG00000232608 100862727 40588550 - 40589432 Pseudogene
2 BRWD1-IT1 ENSG00000237373 40589019 - 40591731 processed transcript +
2 METTL21AP1 ENSG00000229623 100421629 40607312 - 40607946 Pseudogene
2 BRWD1-AS1 ENSG00000238141 100874093 40687633 - 40695144 Antisense +
2 Y_RNA ENSG00000252915 40716463 - 40716554 miscellaneous RNA
2 snoU13 ENSG00000238556 40717300 - 40717383 snoRNA
2 RNF6P1 ENSG00000227406 100420924 40745689 - 40748992 Pseudogene
2 MYL6P2 ENSG00000235808 100431168 40860253 - 40860686 Pseudogene ++
2 RPS26P4 ENSG00000228349 692146 40863470 - 40863824 Pseudogene +
2 AF121897.4 ENSG00000235012 40897510 - 40901782 Pseudogene
2 AF064860.5 ENSG00000225330 41002198 - 41098012 processed transcript +
2 AF064860.7 ENSG00000231713 41099682 - 41102607 lincRNA +
2 MIR4760 ENSG00000263973 100616148 41584279 - 41584358 miRNA
2 DSCAM-AS1 ENSG00000235123 100506492 41755010 - 41757285 Antisense
2 SNORA51 ENSG00000207147 41885071 - 41885206 snoRNA
Down Syndrome122
DCR Gene Name Ensembl ID
Entrez
Gene ID
HSA21 coordinates Gene Biotype
Evidence of
expression
(EST)
2 AF064863.1 ENSG00000221396 41949429 - 41949538 miRNA +
2 DSCAM-IT1 ENSG00000233756 100874326 41987304 - 42002693 sense intronic ++
2 YRDCP3 ENSG00000230859 100861429 42235920 - 42236399 Pseudogene
2 LINC00323 ENSG00000226496 284835 42513427 - 42520060 Antisense
2 MIR3197 ENSG00000263681 100423023 42539484 - 42539556 miRNA
2 AL773572.7 ENSG00000225745 42548249 - 42558715 processed transcript ++
2 BACE2-IT1 ENSG00000224388 282569 42552024 - 42552553 Antisense +
2 AP001610.5 ENSG00000228318 42813321 - 42814669 Antisense +
Table 2. Summary of the non-protein-coding elements contained by the DSCR. The first column indicates whether the
genes belong to the DCR-1, to the DCR-2 or to the overlap region. Elements are given in their physical order, starting
from the more centromeric sequence. Genomic coordinates refer to the HG19 version of the human genome
sequence. The evidence for expression is derived from the ESTs linked to the Ensembl genome browser. + = at least
one EST sequence supporting the Ensemble prediction. ++ prediction supported by several EST sequences.
2. Functional analysis of the DSCR through mouse models
Animal models are essential to understand the molecular pathogenesis of DS. Moreover,
although none of them can faithfully mimic the human situation, they are crucial for the
preclinical development of new therapeutic strategies. The availability of sophisticated tools
for mouse genetics and the conserved synteny between mouse chromosome 16 (MMU16) and
HSA21 have provided the basis for the development of many mouse models of DS, allowing
to test the critical region concept and to perform a genetic dissection of the complex DS
phenotype.
The first mouse models have been obtained by studying the effects of partial trisomies of
MMU16 derived from Robertsonian translocations. These mice live until adulthood and show
many clinical phenotypes similar to DS patients, in particular the neuropathological and
neurobiological alterations, including learning and behavioral abnormalities [22-25]. The most
studied mouse model for DS is theTs65Dn mouse, which possesses an extra copy of the distal
13 Mbp part of MMU16, including ~ 104 mouse genes orthologous to those on HSA21 [23].
These mice show a number of developmental and functional parallels with DS, including
craniofacial abnormalities and behavioural changes [26-32]. Moreover, they show alterations
in the structure of dendritic spines in cortex and hippocampus [33] and reduced long-term
potentiation (LTP) in the hippocampus and fascia dentata (FD) [34-36].
Ts1Cje mice, which are trisomic for a shorter but fully overlapping segment of MMU16 (~81
genes), show similar changes, usually to a lesser degree [24,25,37,38]. Comparison of the
behavioral performances of the Ts1Cje and Ts65Dn showed that the learning deficits of Ts1Cje
mice are similar to those of Ts65Dn. The data obtained from these models strongly supported
the concept of DSCR, because they indicated that conserved genes are capable to influence
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cognition through their dosage lie in a region spanning from Sod1 to Mx1, which contains the
mouse counterpart of the human DCR-1.
Probably, the most elegant studies that have addressed the role of the mouse genome region
syntenic to the human DSCR are those undertaken by Roger H. Reeves and coworkers. Using
chromosome engineering, this group has generated a mouse line referred to as Ts1Rhr, trisomic
for a segment closely corresponding to the DCR-1 region, as defined by [10] and [11] and
including 33 genes [39]. Moreover, they obtained the corresponding deletion, resulting in the
monosomic line Ms1Rhr. Interestingly, the first results produced by the analysis of these
models did not confirm strongly the DSCR hypothesis. Indeed, the craniofacial dysmorphol‐
ogies of Ts1Rhr are less marked and distinct from those detected in Ts65Dn and Ts1Cje mice
[39]. Furthermore, no differences were initially detected between Ts1Rhr and normal controls
in the Morris water maze, in the induction of LTP in the hippocampal CA1 Region and in the
hippocampal and in cerebellum volume [39-41]. These results seemed to suggest that tripli‐
cation of the Ts1Rhr segment is not sufficient to produce these correlates of DS phenotypes.
However, the intercross of the monosomic line Ms1Rhr with the Ds65Dn line, which restored
in a disomic condition for DCR-1 genes, generated mice showing normal performances in the
Morris water maze, indicating that trisomy of DCR-1 is necessary for these cognitive pheno‐
types [41]. Importantly, a more recent report established that, if the Ts1Rhr mutation is
analyzed on the same genetic background of the Ts65Dn and Ts1Cje mice and with more
stringent tests, important cognitive and synaptic neurobiological phenotypes can be detected
[42]. In particular, 20 of 48 phenotypes, many of which are shared with Ts65Dn mice, distin‐
guished Ts1Rhr animals from their 2N controls. In addition to the genetic background
difference, it must be noticed that the task used in this work was less stressful and more
sensitive than the water maze, which may further account for the initial discrepancy [42]. These
phenotypes were correlated with changes in synaptic density and in dendritic spine morphol‐
ogy, further indicating that DCR-1 genes strongly contribute to these abnormalities [42]. In
conclusion, taken together, these results provide strong support to the view that increased
dosage of DCR1 genes is necessary and sufficient to confer to mice some of the neurobiological
phenotypes characteristic of DS.
The use of mouse genetic tools has allowed the production of even more restricted models,
addressing the role of specific subregions of the human or mouse DSCR, or even the role of
single DSCR genes. For instance, the isolation from the DSCR of huge genomic clones main‐
tained as Yeast Artificial Chromosomes (YAC) or as Bacterial Artificial Chromosomes (BAC)
and their microinjection in mouse oocytes has allowed the generation of transgenic lines
covering the entire length of the human DSCR [43-45]. The characterization of these mice has
shown that the approach can be very useful to study the function of specific genes. However,
it became also clear that this strategy is of limited usefulness to establish genes contribution
to the phenotype. For instance, BAC transgenesis allowed the production of a mouse line
carrying a single extra copy of the DYRK1A gene [46]. Interestingly, these mice showed
impaired cognitive behaviours, but they were characterized by increased hippocampal LTP,
while all the models discussed above show depressed hippocampal LTP [46]. The same
conclusion applies even better to the models obtained through classical transgenesis ap‐
Down Syndrome124
proaches, in which a single human or mouse gene is inserted in the mouse genome in the form
of a cDNA driven by a non-physiological promoter [47].
On the other hand, the combination of gene targeting technologies with the “classical” DS
model discussed above allows a subtractive strategy, providing the most stringent test to
address the relevance of single genes for the overall phenotype. Indeed, once a null allele for
a DSCR gene is available, a compound mutant can be generated, carrying the specific mutation
in a trisomic background. The subtractive approach allowed to detect a significant rescue of
the phenotype in the case of some DS-related genes, belonging to the DSCR as in the case of
DSCR1[48], Olig1 and Olig2 [49], or even external to it, as in the case of APP [50,51].
3. Functional role of DSCR genes in DS intellectual disability: Towards the
identification of drugable pathways
In the following section we will summarize the most relevant functional information available
on DSCR genes, trying to especially underscore their implication in molecular networks
relevant to intellectual disability. As it is obvious from the previous sections, this discussion
will involve not only genes that strictly belong to the DSCR, but also their interactions with
other HSC21 genes, whose functional involvement is supported by abundant literature. In
particular, we will try to discuss as much as possible the single DSCR genes on the basis of
their common features. The essential information about genes not included in this section is
reported in Tables 1 and 2. While deploying this summary, we will also provide a perspective
of how this information can be useful for progressing towards the development of new
therapeutic strategies that may take into account the complex nature of DS.
3.1. Pathogenesis of intellectual disability in DS
In order to evaluate the possible degree of functional involvement for specific genes, it is
very important to briefly analyze the principal biological processes that have been to cogni‐
tive impairment in the DS. To this regard, studies performed both in humans and in ani‐
mal models have shown that trisomy 21 leads to an unbalance of key cellular events, such
as neuronal cell  proliferation and differentiation, which can be detected during develop‐
ment and post-natal life using morphological methods [52,53]. Importantly, these defects
may coexist with or may be causally related to functional deficits, that can be revealed us‐
ing sophisticated physiological methods [52,53]. Reduced neurons number is found in cor‐
tex, hippocampus and cerebellum of DS brain and are accompanied by impaired neuronal
function. Brain hypocellularity is acquired during early developmental stages and is paral‐
leled by impaired cognitive development leading to intellectual disabilities. Further deteri‐
oration  of  cognitive  abilities  occurs  in  adolescence  and  adulthood,  possibly  due  to
degenerative mechanisms [28]. Although the syndrome invariably results in AD-like neuro‐
pathology, the actual onset of dementia is quite variable. The availability of genetic models
of trisomy 21 has been instrumental in gaining insights into the pathogenic mechanisms
leading to DS cognitive disability. Morphological abnormalities of neuronal dendritic com‐
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partment are paralleled by functional electrophysiological deficits and impairment of learn‐
ing and memory, pointing to the existence of defective neural network connectivity and
faulty  neuronal  communication  as  primary  determinants  of  DS  cognitive  disabilities
[34-38,42,54]. Such pathological scenario arises from a combination of neurodevelopmental
abnormalities and neurodegenerative processes. Addressing which processes are irreversi‐
ble and which ones can be prevented or reverted by manipulating genes and pathways is
of paramount importance for the development of new therapeutic strategies. Although the
crossover between neurogenesis dysfunction and neurodegeneration is still poorly under‐
stood, it is likely that common pathways differentially affect various cellular functions dur‐
ing development and aging. Thus, the developmental aspects are fundamental in defining
the most important functional consequences of the genetic imbalance in DS at the cognitive
level. However, the IQ of DS patients decreases in the first decade of life, indicating that
the maturation of central nervous system is compromised [8]. Indeed, on one side, different
observations suggest that neurogenesis impairment starting from the earliest stages of de‐
velopment may underlie the widespread brain atrophy of DS, the delayed and disorgan‐
ized lamination in the DS fetal cortex [55] and hippocampal hypoplasia [56]. On the other,
postmortem studies show that DS patients start their lives with an apparently normal neu‐
ronal  architecture  that  progressively  degenerates.  During  the  peak  period  of  dendritic
growth and differentiation (2.5 months old infants), no significant differences were detect‐
ed in dendritic differentiation between euploid and DS cases in pyramidal neurons of pre‐
frontal cortex [57]. Similarly, DS infants younger than 6 months showed greater dendritic
branching and length than normal infants [58] [59] in contrast to the reduced number of
dendrites and degenerative changes in DS children older than two years [60].
3.2. Transcription factors and co-factors encoded by the DSCR
The DSCR contains 6 genes encoding for transcription factors (Table 1), which are likely to
play crucial roles in determining DS phenotypes, considering their potential to affect many
cellular networks. Two of them, ERG and ETS2 belong to the erythroblast transformation-
specific (ETS) family. Members of this family are key regulators of embryonic development,
cell proliferation, differentiation, angiogenesis, inflammation, and apoptosis [61]. ERG is
required for vascular cell remodeling and hematopoesis [62,63], while ETS2 has been linked
to thymocytes development and apoptosis [64]. Together with RUNX1 [65], these proteins are
very likely to contribute to the hematological abnormalities that characterize DS, but not to
contribute significantly to ID. In contrast, BRWD1 and HGMN1 are two proteins highly
expressed in brain that is involved in chromatin-remodeling [66,67]. Importantly, HGMN1 has
been found to regulate the expression of the ID gene MeCP2 [67]. Under the same perspective,
another interesting candidate is the bHLH factor SIM2 that together with its paralog SIM1 is
the homolog of Drosophila single-minded (sim) gene. The Drosophila sim gene encodes a
transcription factor that is a master regulator of fruit fly neurogenesis [68], raising the possi‐
bility that SIM2 could perform a similar function in mammals. However, a role of SIM2 in
mammalian neurogenesis has not been so far confirmed, while this gene has been shown to
repress myogenesis in mouse [69]. Besides to directly regulating transcription, DSCR genes
could strongly modulate the activity of transcription factors encoded by other loci. The best
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characterized example is RCAN1, which was initially named DSCR1 [70]. The gene name was
then changed after realizing that the encoded protein inhibits calcineurin-dependent tran‐
scriptional responses by binding to the catalytic domain of calcineurin A and interfering with
the phosphorylation of the NFAT transcription factor [71,72]. RCAN1 is overexpressed in DS
brain [14,73] and seems to play a key role in the regulation of mitochondrial function and
oxidative stress. Indeed, the Drosophila homolog of RCAN1 especially affects the activity of the
mitochondrial ADP/ATP translocator [74]. Moreover, it has been shown that, when RCAN1 is
overexpressed in PC12 cells, it induces the expression of superoxide dismutase type 1 (SOD1)
[75], which is encoded by another HSA21 gene [15] and is upregulated in DS brain [76].
Importantly, RCAN1 acts as a stress response element: its acute overexpression protects cells
from oxidative stress [77]. Indeed, RCAN1 overexpression may have beneficial effects by
counteracting the oxidative damage associated with DS. Elevated levels of DNA damage, lipid
peroxidation [78] and pro-oxidant state develop early in life in DS subjects [79]. Nevertheless,
it is very likely that the benefits arising from these actions on oxidative stress may be overcome
by the long-term detrimental effects on synaptic functions and neuronal survival due to the
chronic RCAN1 overexpression, which will be discussed in sections 3.4 and 3.5.
3.3. Signaling proteins encoded by the DSCR
Modifications  of  the  cellular  cytoskeleton  in  response  to  extracellular  stimuli,  such  as
growth factor engagement and cell-cell contacts are essential for neuronal proliferation, for
the  formation of  axons and Dendrites,  for  the  differentiation and for  the  establishment,
maintenance  and  remodeling  of  neuronal  connections.  Many  of  the  well-characterized
DSCR genes, such as DSCAM, CLDN14, PIGP, LCA5L, IGSF5 and FAM3B are implicated
in these processes. However, the best characterized proteins belonging to this category are
DYRK1A and TTC3.
3.3.1. DYRK1A
DYRK1A, dual-specificity tyrosine-phosphorilation-regulated kinase1A, encodes a protein
kinase capable to phosphorylate serine, threonine and tyrosine residues, highly conserved at
the aminoacidic level across vertebrates and invertebrates [80]. The orthologus Drosophila gene
is involved in neuroblast proliferation and it is named minibrain (MNB), because null mutations
affect post-embrionic neurogenesis, resulting in reduced brain size [81]. The highly conserved
structure of this kinase and its mapping to the DSCR prompted extensive studies on its
vertebrate homologues [82]. These studies have revealed that the dosage of DYRK1A is
extremely important to normal brain development. Indeed, mice homozygous for a null
mutation of DYRK1A die early in development and even heterozygous mice display reduced
viability and a smaller brain, characterized by reduction of neuronal counts in specific regions
[83]. Accordingly, truncation of the human MNB⁄DYRK1A gene has been reported to cause
microcephaly [84,27]. Furthermore transgenic mice overexpressing DYRK1A show severe
impairment in spatial learning and memory in the Morris water maze tests, indicating
hippocampal and prefrontal cortical function alteration [45,85]. Moreover, these transgenic
mice show abnormal LTP and LTD, indicating synaptic plasticity alterations [46]. These defects
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are similar to those found in murine models of DS with trisomy of chromosome 16, suggesting
a causative role of DYRK1A in cognitive disorders present in DS patients. DYRK1A is ex‐
pressed in the cortex, in the hippocampus and in the cerebellum [86,18] and is overexpressed
in the mouse trisomic model Ts65Dn [87], in DS fetal brain and other trisomic tissues [88].
These data obtained from different experimental systems have revealed various possible
functions of DYRK1A in central nervous system (CNS) development, including its influence
on proliferation, neurogenesis, neuronal differentiation, cell death and synaptic plasticity [46,
89-92]. These multiple biological functions of DYRK1A are due to its interactions with
numerous cytoskeletal, synaptic and nuclear proteins, including transcription and splicing
factors [93]. Together with other studies [85,94-96], these data strongly support the involve‐
ment of Dyrk1A in several neuropathological phenotypes and in the cognitive deficits that
characterize Down syndrome. More recently, the observation that DYRK1A is overexpressed
in the adult DS brain [97] implicated this protein also in the DS neurodegenerative phenotype.
In particular, DYRK1A overexpression appears to be the cause of gene dosage-dependent
modifications of several mechanisms that may contribute to the early onset of neurofibrillary
degeneration. In fact, it has been demonstrated that Dyrk1A phosphorylates tau at several sites
in vitro [98] and such sites are phosphorylated in DS brain [99]. Dyrk1A-induced tau phos‐
phorylation inhibits the biological activity of tau, primes it for further phosphorylation by
glycogen synthetase-3β (GSK- 3β) and promotes its self-aggregation into neurofibrillary
tangles (NFTs) [99]. Interestingly, besides to phosphorylating protein, DYRK1A also colocal‐
izes with NFTs [100]. In addition, neuropathological and molecular studies indicate that
overexpressed nuclear DYRK1A contributes to the modification of the alternative splicing of
Tau leading to neurofibrillary degeneration [101,102]. Neurofibrillary degeneration is the
leading cause of neuronal death and dementia in Alzheimer’s disease (AD) and in DS⁄AD. The
multi-pathway involvement of DYRK1A in neurofibrillary degeneration indicates that
therapeutic inhibition of the activity of overexpressed DYRK1A may delay the age of onset
and inhibit the progression of neurodegeneration in DS. To this regard, the studies recently
performed by the group of Delabar [103] represent, arguably, the best example of how the
functional knowledge about DSCR genes can be translated into new potential therapeutic
strategy. Indeed, this research group has found that Epigallocatechin gallate (EGCG) - a
member of a natural polyphenols family, found in great amount in green tea leaves - is a specific
and safe DYRK1A inhibitor and that its administration can revert the brain defects induced by
overexpression of DYRK1A [103]. Together with a previous report showing that EGCG
administration may beneficially affect the LTP abnormalities detected in Ts65Dn mice [104],
this study paved the way for the promotion of clinical trials, which are already in Phase 2 (see
for instance http://clinicaltrials.gov/ct2/show/NCT01394796).
3.3.2. TTC3
Since its discovery in 1996, the TTC3 gene has been considered an important candidate for the
CNS-related phenotypes that characterize DS, because of its mapping within the DSCR
[105,106]. This hypothesis was further supported by the analysis of TTC3 expression during
normal development. Indeed, during mouse and human brain embryogenesis, TTC3 expres‐
sion shows regional and cellular specificities well correlated with the anatomical defects
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observed in DS patients [55,107]. In particular, TTC3 is expressed at highest levels in the post-
mitotic areas of central nervous system (CNS), suggesting a role in neuronal cell differentiation
[108,109]. Moreover, it has been reported that the expression of TTC3 is increased in tissues
and in cells derived from DS experimental models [110] and from DS individuals [111,112]. In
2007, on the basis of both overexpression and knockdown experiments performed in PC12
neuroblastoma cells, we demonstrated that the TTC3 protein may play a pivotal role in
regulating the differentiation program of neuronal cells, starting from the earliest stages [113].
More specifically, increased TTC3 function strongly prevents the neurite sprouting normally
elicited by NGF-treatment, while TTC3 knockdown increases neurite length [113]. Important‐
ly, TTC3 may affect not only the generation of neuronal processes, but also their maintenance
(Berto et al., unpublished)., and its effects on neuronal differentiation are mediated by the
activation of a specific pathway comprising the master cytoskeletal regulator RhoA and its
effettor proteins, namely Citron-isoforms [113] Rho kinases (ROCKs) and LIM-kinase (Berto
et al., in preparation), which have been implicated in all the different aspects of the neuronal
differentiation program [114] and in different aspect of cognitive disorders [115]. Importantly,
specific inhibitors of ROCKs, such as Fasudil, have been already approved by FDA, and
therefore represent ideal candidates for testing in the experimental models [116]. In addition,
a recent report by the group of Dr. M. Noguchi has shown that TTC3 can down-modulate the
activity of the Akt kinases (AKTs), by promoting their ubiquitination and degradation [111].
This observation is particularly important, not only because AKTs have been shown to regulate
neuronal survival [117], axonogenesis [118], dendritogenesis and synaptogenesis [119], but
especially because these proteins are effectors of the PI3K pathway, which is the subject of
extensive pharmacological investigation, in light of its centrality in cancer and inflammation
research [120,121].
3.4. Gene networks affecting the excitatory-inhibitory balance in DS
The majority of forebrain is comprised of excitatory glutamatergic projection neurons and
approximately 10% inhibitory γ-amminobutyric acid (GABA) interneurons. The normal
functioning of the neural networks underlying cognitive functions depend on a finely-tuned
balance of excitatory and inhibitory activities [122]. Accordingly, different reports have
supported the possibility that cognitive impairment in DS models can be related to specific
alterations of the excitatory/inhibitory balance, which may result from the direct action of
DSCR genes or from more indirect mechanisms. For instance, it has been hypothesized that
the increased dosage of HSA21 gene could favor the excitatory inputs in the hippocampus by
increasing the activity of N-methyl-D-aspartate (NMDA) receptor (NMDAR), with potential
effects on synaptic plasticity and neuron survival [123]. This theory was based on the obser‐
vation that that several HSA21 genes, such as APP, SOD1, RCAN1 and DYRK1A, directly
interact or indirectly affect the activity of the NMDARs. The best characterized pathway is that
involving RCAN1, which regulates NMDARs by directly binding and inhibiting the calci‐
neurin protein phosphatase (CaN) [71,77,124]. NMDARs are CaN targets [125] [126] and CaN
inhibition leads to increased NMDARs [127] activity, by decreasing channel open probability
and mean time [127]. On this basis Costa and co-workers hypothesized that the noncompetitive
NMDA antagonist memantine, which acts as open channel blocker and is currently approved
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for AD therapy, could mimic the actions of CaN and restore normal NMDARs function,
possibly improving learning and memory [123]. Indeed, memantine ameliorates contextual
fear conditioning learning in 4–6- and 10–14-month old Ts65Dn mice when administered at 5
mg/kg by acute intraperitoneal injection before context exposure. Despite these studies, a
recently published clinical trial reported that memantine is not an effective pharmacological
treatment for cognitive decline or dementia in DS patients who are above 40 years old [128].
This suggests that therapies that are effective in DS models and in AD patients may not
necessarily confer benefits in DS.
More consistent reports have shown that the LTP phenotypes and the reduced performance
in cognitive tests observed in mouse models could be the result of excessive GABA-ergic
responses, producing a net decrease of synaptic output [36,37,129]. This phenomenon could
be a direct effect of the overexpression of at least three proteins encoded by the DSCR, namely
the chloride channel CLIC6 and the rectifying potassium channels KCNJ6 and KCNJ15.
Accordingly, primary hippocampal neurons derived from Ts65Dn mice display a significant
increase in GABA-mediated GIRK currents, consistent with the increased expression of
KCNJ6/GIRK2 [130]. However, some of the data are also consistent with an increased pre-
synaptic availability of GABA [129], produced by undefined and probably indirect mecha‐
nisms. On this basis, several pharmacological interventions have been proposed to restore the
excitatory-inhibitory imbalance by decreasing the excessive inhibition of GABAergic neuro‐
transmission prevalent in DS mouse models [131]. In particular, Ts65Dn mice have been treated
with non-competitive GABAA antagonists, pentylenetetrazol (PTZ) and picrotoxin (PTX),
which inhibit GABAA receptors. Chronic treatment with PTZ reversed the deficits seen in the
novel object recognition task (NORT) and spontaneous alternation tasks in Ts65Dn mice
[129,132]. Surprisingly, the improvement in cognition and LTP was sustained for up to 2
months after initial treatment, suggesting a long-lasting effect on neuronal circuit modification.
Chronic treatment with PTZ for 8 weeks in Ts65Dn mice did not modify sensorimotor abilities
and locomotor activity in home cages. However it did rescue learning and memory perform‐
ance in the Morris water maze (MWM) task [133]. Recently, chronic treatment in Ts65Dn mice
with an inverse agonist selective for the α5 subunit of the GABAA benzodiazepine receptor
(α5IA) improved cognitive deficits in the MWM and normalized Sod1 overexpression with an
enhancement in learning-evoked immediate early genes expression levels [134]. Encouraged
by this body of evidence, Roche, a healthcare company, recently announced the commence‐
ment of a trial to examine the cognitive impact of reducing GABA-ergic neurotransmission in
the hippocampus using a drug selective for the α5 subunit of GABAA receptors (http://
www.roche-trials.com).
Finally, the imbalance in excitatory/inhibitory ratio could be the result of abnormal neurogen‐
esis. Indeed, reduced cell numbers in the DS hippocampus could be caused by impaired adult
neurogenesis, which has been observed in Ts65Dn [135] [136] and Ts1Cje mice [137]. Therefore,
approaches targeting neurogenesis seem very promising for DS therapy. Interestingly, a
fascinating connection has been documented between the DSCR gene KCNJ6 and adult
neurogenesis, mediated by serotonin signaling. DS has long been associated with defects in
the serotonergic system [138]. In particular, the serotonin 5-HT1A receptor expression peaks
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earlier in developing DS brains and decreases to below normal levels by birth [139]. Moreover
reduced 5-HT levels are present in adults with DS [140]. Since 5-HT depletion causes a
permanent reduction in neuron number in the adult brain [138], it is conceivable that altera‐
tions in the serotonergic systems during early life stages may contribute to the reduced
neurogenesis of the DS brain. Activity of the serotonin receptor 1A (5HTR1A) is required for
adult neurogenesis in the hippocampus [141] and is mediated by the potassium channel
KCNJ6. Overexpression of KCNJ6, as in the Ts65Dn, may over-inhibit presynaptic 5HTR1A,
causing reduced levels of serotonin. Fluoxetine, an antidepressant that inhibits serotonin (5-
HT) reuptake, inhibits KCNJ6 and increases presynaptic levels of serotonin. Consistent with
this, it has been already demonstrated that fluoxetine is able to rescue neurogenesis in the adult
Ts65Dn [135]. Recently, treatment during the early postnatal period restored neurogenesis and
the total number of neurons in the dentate gyrus. This effect was accompanied by the full
recovery of a cognitive task [142]. The releance of these data is even greater if considering that
fluoxetin is an antidepressant widely used by adults and prescribed in children and adoles‐
cents [143] and that it does not seem to have negative effects on post-natal development [144].
3.5. The DSCR and Alzheimer-related molecular networks
Most DS patients experience a decline in cognition during adulthood, followed by the
development of classical Alzheimer’s disease (AD) neuropathology, characterized by the
accumulation of amyloid plaques containing high levels of the A-beta fragments of the APP
protein, by neurofibrillary tangles containing high levels of hyperphosphorylated Tau protein
and by massive neurodegeneration [145]. Increased dosage of the APP gene, which is located
outside the DSCR, is very likely the most important factor that underlies this phenomenon
[146]. Indeed, increased dosage of APP is sufficient to strongly increase the risk of AD, since
APP gene duplication has been detected as the mutation responsible for some early-onset
familial cases of AD [147]. The link between AD and the APP gene has been further strength‐
ened by the finding that an extra copy of APP seems to be necessary for the development of
AD in DS. Indeed, it has been reported the case of an old patient affected by DS but not showing
any signs of dementia [148]. At autopsy, plaques and tangles were absent in the brain of this
individual. The patient had a segmental trisomy HSA21, not including the APP gene [148].
These data strongly support that the early onset of AD pathology in DS is in part due to
overexpression of the APP gene. The data obtained from experimental models further support
the crucial role of APP in DS [51]. Indeed, it has been shown that APP overexpression in Ts65Dn
impairs the retrograde transport of nerve growth factor (NGF) from the hippocampus to the
basal forebrain, causing the degeneration of BFCN [51], which significantly degenerates in
Ts65Dn. Importantly, APP is one of the few genes for which a successful subtractive genetic
approach has been reported, since restoring APP gene dosage to two copies in the Ts65Dn
model corrected the water maze phenotype and prevented BFCN degeneration [50,51]. Finally,
APP-mediated pathological mechanism may also contribute to the developmental abnormal‐
ities detected in mouse models, since it has been suggested that APP overexpression can result
in increased Notch signaling pathway, which is crucial for neuronal and glial differentiation
[149]. However, it is conceivable that also some of the DSCR genes may cooperate with APP
in accelerating the AD-related neuropathological phenotypes observed in DS patients. In
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particular BACE2 could promote the beta-cleavage of APP, further increasing the amount of
generated A-beta peptides [150-152]. DYRK1A can also play an important role, because it can
stimulate the phosphorylation of APP and Tau, resulting in increased cleavage and aggrega‐
tion, respectively [98,153]. Finally, Tau hyperphosphorylation can be stimulated by increased
expression of RCAN1, since phosphorylated Tau is one of the substrates of calcineurin [154].
Moreover, it has been shown that this activity of RCAN1 can be modulated by DYRK1A [155]
Therefore it is very likely that the development of new approaches aimed at targeting these
proteins could turn out to be beneficial both for AD and for DS management.
3.6. DSCR-dependent RNA-networks
As it is generally the case for the human genome, besides to protein coding genes, the DSCR
contains many sequences that have been so far almost completely neglected, because they are
not predicted to encode for proteins [16]. However, as we show in Table 2, on the basis of the
current knowledge, many of these loci display features indicating that they could be func‐
tionally relevant and could contribute to the pathogenesis of DS phenotypes. Indeed, besides
to the two copies of snRNAs and five copies of snoRNAs associated to splicing factors, the
DSCR contains many regions that are transcribed to produce processed transcripts, devoid of
coding potential. Some of these sequences, such as antisense transcripts, processed pseudo‐
genes and sequences located in proximity of promoters, are closely associated to functioning
genes, and could be involved in their regulation, as it has been shown in many other cases
[156-158]. In many other cases, the genes appear to produce llincRNAs, that could act in cis to
modify chromatin structure, or in trans to modify gene expression at the transcriptional and
post transcriptional level, as it has been shown in the cases of HOTAIR [159] and of LincRNA-
p21 [160,161]. Although the function of these molecules is at the moment completely unknown,
their study could be extremely interesting. Indeed many of these sequences have been
implicated in the epigenetic and in the post-transcriptional control of gene expression.
Moreover, since these sequences diverge much more rapidly than the sequences of protein-
coding genes, it is very likely that they could be strongly implicated in the control of human-
specific features and phenotypes. Therefore, it seems reasonable to anticipate that the
functional study of lincRNA-encoding genes in DS models and the study of their variation in
humans will be a fertile ground for future research. Finally, the DSCR contains at least three
genes encoding miRNA precursors (probably five, if considering also those that have only
been predicted). Interestingly, mir-802, which is encoded by the DSCR, and mir-155, which is
located on HSA21 in a more centromeric position, have been shown to repress the expression
of MeCP2 [162], whose inactivation is the cause of Rett syndrome. Since MeCP2 is also
repressed by HMGN1, this study further underscore the potential relevance of MeCP2
repression in DS and provides a very interesting example of how the intertwining of tran‐
scription and post-transcriptional regulatory networks dependent on DSCR genes can produce
intellectual disability. Considering the reported reversibility of MeCP2 downregulation
phenotypes [163] and the great efforts that are being dedicated to identify drugable pathways
downstream of MeCP2 [164], it is conceivable that the functional exploration of these networks
in DS could be also relevant for the development of future therapies.
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4. Concluding remarks
Functional information on HSA21 genes is still quite partial and mostly limited to a subset of
protein-coding genes. However, the recent success in DS models of therapeutic strategies
targeted either on specific DSCR genes, or even on much broader mechanisms, justifies to our
opinion an optimistic view of the future. In particular, we think that it will be reasonable to
expect that a high level of understanding of the complex networks implicating DSCR genes
through systems biology approaches will provide very useful insight, which could be trans‐
lated into new therapies that could turn out to be useful not only for DS, but also for other
disorders such as Alzheimer’s disease and Rett syndrome.
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